| 前收市價 | 9.01 |
| 開市 | 9.03 |
| 買盤 | 8.88 x 200 |
| 賣出價 | 9.05 x 100 |
| 今日波幅 | 8.80 - 9.10 |
| 52 週波幅 | 5.67 - 30.99 |
| 成交量 | |
| 平均成交量 | 1,101,687 |
| 市值 | 466.155M |
| Beta 值 (5 年，每月) | 1.60 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -1.81 |
| 業績公佈日 | 2024年7月31日 - 2024年8月05日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 40.44 |
BenzingaWhy Is EyePoint Pharmaceuticals Stock Plummeting On Monday?
On Monday, EyePoint Pharmaceuticals Inc. (NASDAQ:EYPT) announced the topline results of its Phase 2 PAVIA trial evaluating Duravyu (vorolanib intravitreal insert), previously known as EYP-1901, in patients with non-proliferative diabetic retinopathy (NPDR). The data demonstrated that Duravyu has a biologic effect in patients with NPDR and a favorable safety and tolerability profile; however, the trial did not meet the pre-specified primary endpoint. The company plans to provide an update on the
Insider MonkeyEyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q4 2023 Earnings Call Transcript
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q4 2023 Earnings Call Transcript March 7, 2024 EyePoint Pharmaceuticals, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning. My name is Kevin and I will be your conference operator today. At this time, […]
ZacksCompared to Estimates, EyePoint Pharmaceuticals (EYPT) Q4 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for EyePoint Pharmaceuticals (EYPT) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
